Main Article Content
Aims: hypovitaminosis D may be related to the pathogenesis of the nonalcoholic fatty liver disease (NAFLD) and may contribute to NAFLD's development and progression. Our study aimed to evaluate the therapeutic effects of vitamin D supplementation in patients with NAFLD.
Place and Duration of Study: Department of Gastroenterology, Affiliated Hospital of Inner Mongolia University for the Nationalities, China, between January 2020 and September 2020.
Methods: A total number of 166 patients were randomly divided into treatment group (n=86) and control group (n=80) with elevated levels of AST (aspartate aminotransferase) and ALT (alanine aminotransferase) with hypovitaminosis D, with high or normal levels of T.G. (triglyceride), TCHO (total cholesterol), LDL-C (low-density lipoprotein C), HDL-C (high-density lipoprotein C). The treatment group received vitamin D 400 units twice a day along with lifestyle modifications as SMT (standard medical Treatment) (vitamin D+SMT), and the control group only received lifestyle modifications (SMT) for 6 months. The study's primary objective was to assess an improvement in elevated serum AST, ALT, T.G., TCHO, LDL-C, HDL-C, and the secondary purpose was to observe whether vitamin D can improve hypovitaminosis D in the patients with NAFLD.
Results: after 6 months of the treatment with vitamin D supplementation, a significant improvement in serum AST and ALT was observed in treatment group (vitamin D+SMT) when they were compared with control group (SMT) as, (ALT: vitamin D+SMT, 57.635±4.882 and 57.581±4.817(u/l) p value=0.033 vs SMT, 59.958±5.715 and 59.909±5.690(u/l) p value=0.07) and AST (AST: vitamin D+SMT, 46.920±4.162 and 46.864±4.145(u/l) p value=0.03 vs SMT, 50.270±4.060 and 50.256±4.053(u/l) p value=0.117). An improvement in vitamin D levels were observed only in treatment group (vitamin D+SMT) as, (VD: vitamin D+SMT, 20.985±3.732 and 21.049±3.684 (ng/ml) p value= 0.014 and SMT, 26.665±1.534 and 26.594±1.484 (ng/ml) p value=0.011).
Conclusion: In the patients with NAFLD, administration of vitamin D supplementation and lifestyle modifications can significantly improve serum ALT, AST, and vitamin D levels.
Maurice J, Manousou P. Non-alcoholic fatty liver disease. Clinical Medicine (London). 2018;18(3):245-250.
El-Agroudy NN, Kurzbach A, Rodionov RN et al. Are lifestyle therapies effective for NAFLD treatment? Trends Endocrinol Metab. 2019;30(10):701-709.
Younossi ZM, Koenig AB, Abdelatif D et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73-84.
Tanaka N, Kimura T, Fujimori N et al. Current status, problems, and perspectives of nonalcoholic fatty liver disease research. World Journal of Gastroenterol. 2019;25(2):163-177.
Schwenger KJ, Allard JP. Clinical approaches to nonalcoholic fatty liver disease. World Journal of Gastroenterol. 2014;20(7):1712-1723.
Patil R, Sood GK. Nonalcoholic fatty liver disease and cardiovascular risk. World Journal of Gastrointestinal Pathophysiology. 2017;8(2):51-58.
Tana C, Ballestri S, Ricci F et al. Cardiovascular risk in nonalcoholic fatty liver disease: Mechanisms and therapeutic implications. International Journal of Environmental Research Public Health. 2019;16(17):3104.
Houghton D, Stewart CJ, Day CP, Trenell M. Gut Microbiota and Lifestyle Interventions in NAFLD. International Journal of Molecular Sciences. 2016;17(4):447.
Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nature Reviews Gastroenterology and Hepatology. 2016;13(7):412-425.
Ahmed IA, Mikail MA, Mustafa MR et al. Lifestyle interventions for nonalcoholic fatty liver disease. Saudi Journal of Biological Sciences. 2019;26(7):1519-1524.
Mahjoubin-Tehran M, De-Vincentis A, Mikhailidis DP et al. Nonalcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis. Molecular Metabolism. 2020; 101049.
Lee I, Park E, Cho J. Association of nonalcoholic fatty liver disease with serum vitamin D levels in combination of physical fitness in Korean older adults. Journal of Steroid Biochemistry and Molecular Biology. 2019;198:105569.
Zadie B, Tadesse S, Wolide AD et al. Non-alcoholic fatty liver disease and associated factors among type 2 diabetic patients in Southwest Ethiopia. Ethiopian Journal of Health Development. 2018; 28(1):19-30.
Ma M, Long Q, Chen F et al. Active vitamin D impedes the progression of nonalcoholic fatty liver disease by inhibiting cell senescence in a rat model. Clinical Research Hepatol Gastroenterol. 2020;44(4):513-523.
WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363(9403):157-163.
Holick MF. The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention. Review in Endocrine Metabolic Disorders. 2017;18(2):153-165.
Wei J, Zhu A, Ji JS. A comparison study of vitamin D deficiency among older adults in China and the United states. Sci Rep. 2019;9(1):19713.
Antonucci R, Locci C, Clemente MG et al. Vitamin D deficiency in childhood: Old lessons and current challenges. Journal of Pediatric Endocrinol Metab. 2018;31(3):247-260.
Yan X, Zhang N, Cheng S et al. Gender differences in vitamin D status in China. Medical Science Monitor. 2019;25:7094-7099.
Pacifico L, Osborn JF, Bonci E et al. Association between vitamin D Levels and nonalcoholic fatty liver disease: Potential confounding variables. Mini-Reviews in Medical Chemistry. 2019;19(4):310-332.
Udomsinprasert W, Jittikoon J. Vitamin D and liver fibrosis: Molecular mechanisms and clinical studies. Biomed Pharmacotherapy. 2019;109:1351-1360.
Arai T, Atsukawa M, Tsubota A, et al. Association of vitamin D levels and vitamin D-related gene polymorphisms with liver fibrosis in patients with biopsy-proven nonalcoholic fatty liver disease. Digestive and Liver Disease. 2019;51(7):1036-1042.
Hourigan SK, Abrams S, Yates K et al. Relation between vitamin D status and nonalcoholic fatty liver disease in children. Journal of Pediatric Gastroenterol Nutrition. 2015;60(3):396-404.
Yoshi T, Orkin S, Arce-Clachar AC et al. Vitamin D deficiency: Prevalence and association with liver disease severity in pediatric nonalcoholic fatty liver disease. European Journal of Clinical Nutrition. 2020;74(3):427-435.
Chávez-Talavera O, Tailleux A, Lefebvre P, Staels B. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology. 2017;152(7):1679-1694.
Chow EC, Maeng HJ, Liu S et al. 1Alpha, 25-dihydroxy vitamin D(3) triggered vitamin D receptor and farnesoid X receptor-like effects in rat intestine and liver in vivo. Biopharma Drug Dispose. 2009;30(8):457-475.
Dabbaghmanesh MH, Danafar F, Eshraghian A, Omrani GR. Vitamin D supplementation for the treatment of nonalcoholic fatty liver disease: A randomized double-blind placebo-controlled trial. Diabetology and Metabolic Syndrome. 2018;12(4):513-517.
Geier A, Eichinger M, Stirnimann G et al. Treatment of nonalcoholic steatohepatitis patients with vitamin D: A double-blinded, randomized, placebo-controlled pilot study. Scandinavian Journal of Gastroenterol. 2018;53(9):1114-1120.
Sakpal M, Satsangi S, Mehta M et al. Vitamin D supplementation in patients with nonalcoholic fatty liver disease: A randomized controlled trial. JGH Open. 2017;1(2):62-67.
Giannini EG, Testa R, Savarino V. Liver enzyme alteration: A guide for clinicians. CMAJ. 2005;172(3):367-379.
Tavakoli H, Rostami H, Avan A et al. High dose vitamin D supplementation is associated with an improvement in serum markers of liver function. Bio Factors. 2019;45(3):335-342.